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Significance of this study
What is already known about this subject?
 ► Diabetes is over represented in patients with 
schizophrenia.
What are the new findings?
 ► The new finding is that both abnormal birth weight 
and first- degree family history of diabetes are inde-
pendent predictors of diabetes onset in clozapine- 
treated population.
 ► Having the two risk factors is strongly associated 
with diabetes development onset after 10 years of 
treatment.
 ► This is very relevant as it could accelerate the imple-
mentation of preventive pharmacological strategies.
 ► Evaluation of these easily accessible risk factors 
should be embedded in routine clinical practice.
How might these results change the focus of 
research or clinical practice?
 ► Early pharmacological interventions might be avail-
able for a subgroup of patients.
AbStrAct
Introduction The prevalence of diabetes in schizophrenia 
is twice that in the general population, but there are few 
reliable predictors of which individuals will develop glucose 
dysregulation.
Objective To test if abnormal birth weight (either too low 
or too high) and parental diabetes, both variables that can 
be ascertained in the clinic, can predict diabetes onset in 
patients with schizophrenia.
Research design and methods Electronic records of a 
cohort of 190 clozapine- treated patients (37% treated for 
more than 20 years) and Cox regression survival analysis 
(with any type of glucose dysregulation as the event) to 
account for differences in length of treatment before the 
event and age at clozapine treatment initiation.
Results Age at clozapine initiation (Exp(B)=1.098; 
p<0.001), family history of diabetes (Exp(B)=2.299; 
p=0.049) and birth weight2 (Exp(B)=0.999; p=0.013) 
were significant predictors of glucose dysregulation onset, 
while gender was not (Exp(B)=0.1.350; p=0.517). Among 
individuals with 10 years of follow- up, 80% of those 
with both abnormal birth weight and a family history of 
diabetes developed diabetes compared with 56% with only 
abnormal birth weight, 40% with only a family history of 
diabetes and 20% in those with neither.
Conclusions Since 48% of cases had at least one risk 
factor and 6% had both risk factors, there is a substantial 
proportion of patients for whom preventive strategies could 
be implemented.
InTROduCTIOn
The prevalence of type 2 diabetes mellitus 
(T2DM) in people with schizophrenia is twice 
that in the general population1 and is a major 
contributor to the reduced lifespan in this 
group.2 There are no risk factors for glucose 
dysregulation specific to this population, 
limiting our ability to identify high- risk indi-
viduals and to use preventive strategies. This 
population might also be exposed to medica-
tions with high potential to induce T2DM but 
to which there is no alternative. Clozapine is 
the only licensed medication for treatment- 
resistant schizophrenia, a lifelong medica-
tion,3 making the need for risk predictors for 
developing T2DM even more pressing in this 
group.
Most of the known risk factors for diabetes 
in people with schizophrenia on antipsychotic 
medication are the same as those in the 
general population, such as age,4 weight 
gain5 6 and a family history of diabetes.7 While 
specific genetic risk variants for T2DM have 
been suggested,8 such data are not yet avail-
able in routine clinical care. Antipsychotic 
use confers an additional risk that is mediated 
through an effect on body weight and a direct 
effect on glucose regulation.9 The association 
between antipsychotic use and weight gain 
is robust, with up to 75% of patients gaining 
weight on many of these drugs,10 thus limiting 
the usefulness of body mass index (BMI) and 
weight gain for risk stratification.
Two clinical factors have been implicated 
in diabetes risk in both the general popu-
lation and in patients with schizophrenia, 
although research in the latter group is 
more limited. The first of these is a parental 
history of diabetes. The association between 
schizophrenia and familial diabetes was first 
described by Henry Maudsley11 12 (‘diabetes is a 
disease which often shows itself in families in which 
insanity prevails’) and has been replicated 
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since.13 14 While parental diabetes increases the risk of 
diabetes in individuals with schizophrenia, this has not 
been specifically examined in the treatment- resistant 
group, who are at higher risk due to their long- term use 
of glucoregulation- altering agents such as clozapine.7
The second factor is abnormal birth weight. A recent 
meta- analysis with over four million individuals showed 
a 50% increase in T2DM onset in those with abnormal 
birth weight,15 defined as either too low (<3000 g) or too 
high (>4500 g). The U- shaped risk curve adds evidence 
to the hypothesis of the fetal origin of the metabolic 
syndrome.16 This hypothesis postulates that intrauterine 
adversity triggers various adaptations in anticipation of 
similar conditions in postnatal life,17 sparing vital organs 
such as the brain at the expense of other organs such 
as the pancreas. This might be protective for immediate 
postnatal survival and remains so if the environment is 
similar,18 but when the postnatal environment does not 
match the predicted one these adaptations increase the 
risk of development of obesity, diabetes and hyperten-
sion. Adverse scenarios for these adaptations include the 
widespread availability of calorie- rich food, or perhaps 
antipsychotic- induced increased appetite and energy 
intake.19 We have previously reported an inverse correla-
tion between birth weight and increased adiposity in 
clozapine- treated patients,20 and more recently that birth 
weight modulates weight gain in drug- naïve patients with 
first- episode psychosis and after clozapine initiation.21 To 
date, there are no published studies on whether abnormal 
birth weight modulates diabetes onset in patients with 
schizophrenia.
We hypothesized that in schizophrenia, abnormal birth 
weight and parental diabetes are independent risk factors 
for diabetes onset. To test this hypothesis, we examined 
clozapine- treated patients, as this population shows the 
highest incidence of diabetes,22 using survival analyses 
accounting for the age of initiation of clozapine and the 
duration of clozapine treatment.23
MeTHOds
design
This was a cross- sectional, single- center study of a 
clozapine- treated cohort at Cambridgeshire and Peter-
borough NHS Foundation Trust in Cambridge, UK. 
Data were collected from anonymized electronic clinical 
records for the period 2013–2018.
sample
In 2013–2018 there were 224 patients with schizophrenia 
who were on treatment with clozapine. Of these, 27 were 
excluded due to missing key data for metabolic assess-
ments, date of diagnosis of glucose dysregulation, or date 
of last primary care blood measurements. A further seven 
cases were excluded as their diagnosis of T2DM predated 
clozapine treatment. Of the remaining 190 individuals, 
data on family history of T2DM were available for 183, 
birthweight data were available for 112, and data on both 
these variables were available for 109 individuals. The 
data are available to other researchers on request.
database validity and assessments
The clozapine research database collects and stores clin-
ical information that is routinely sent in clinical letters to 
the patient and to their general practitioner (GP). Clin-
ical information is collected from both patients and their 
families. As all patients are on long- term follow- up, the 
iteration of communications between the psychiatrist, 
the GP and the patient ensures updating of information 
and minimizes the risk of errors being perpetuated in the 
database. The database contains more than 100 clinical 
variables per assessment and was accessed in May 2018 
for the data included in this study.
study variables
For the survival analysis, data were censored at the point 
of diagnosis of glucose dysregulation (either glucose 
intolerance or T2DM) in the primary care record. The 
following variables were extracted or derived from the 
database: (1) paternal and maternal history of diabetes; 
(2) birth weight (in grams); (3) gender; (4) age; (5) 
parental age at the time of the patient’s birth; (6) dura-
tion of clozapine treatment at the point of censoring; 
(7) presence or absence of glucose dysregulation as per 
primary care records; (8) date of diagnosis of glucose 
dysregulation in primary care; and (9) date of the last 
recorded blood monitoring in primary care.
Glucose dysregulation (which included glucose intoler-
ance) was defined as the main outcome variable, rather 
than a more selective outcome of T2DM. This was driven 
by the clinical relevance of both conditions, given the 
likely progression from glucose intolerance to diabetes.24
Birth weight was routinely collected as part of clinical 
practice. Birth weight was only included if verified by a 
parent or if the patient reported the same birth weight 
at a minimum of two separate consultations, which has 
been reported as a reliable strategy for collecting this 
information.25 Gestational age at the time of delivery was 
not routinely collected and was therefore not available for 
this study. Birth weight was used as a continuous variable 
and as a categorical variable. For the descriptive statistics 
and figures, the following categories were used15: ≤2500 
g (extremely low), 2501–3000 g, 3001–3500 g, 3501–4000 
g, 4001–4500 g and >4500 g (high). For birthweight anal-
yses, there were two categories: a high- risk category that 
comprised the ≤3000 g and >4500 g groups (abnormal 
birth weight), as both have been linked to increased risk 
for diabetes onset in the general population, and a low- 
risk category (3001–4500 g).15
statistical analyses
For the primary survival analysis, the dependent variable 
was the duration from (1) initiation of clozapine to either 
(2a) development of glucose dysregulation or (2b) the 
last recorded metabolic measures in the primary care 
record. To specifically examine the role of paternal and 
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Table 1 Sociodemographic and clinical variables for 
the total study sample and the subgroup with available 
birthweight information
Total
Birthweight 
subgroup
n 190 112
Age in years 48.4 (10.4) 47.1 (9.8)
Gender male 151 (79.8%) 87 (77.7%)
Age at clozapine initiation 
(in years)
31.7 (8.95) 30.7 (8.24)
Years on clozapine 16.5 (7.0) 16.4 (6.95)
On clozapine for >10 years 144 (75.8%) 83 (74.1%)
On clozapine for >20 years 67 (37%) 40 (39%)
Presence of any glucose 
dysregulation
47 (24.7%) 33 (29.5%)
Presence of type 2 diabetes 
mellitus
32 (16.8%) 23 (20.5%)
Family history of diabetes 35 (19%) 23 (21.1%)
Paternal diabetes 18 (9.8%) 12 (11%)
Maternal diabetes 19 (10.4%) 13 (12%)
Paternal age 30.8 (7.5) 30.5 (7.5)
Maternal age 27.2 (5.8) 26.9 (5.4)
Birth weight (g) 3431 (722)
Abnormal birth weight (yes/no) 37 (33%)
Variables are expressed as mean and SD, or number and 
percentage in brackets.
maternal history of T2DM, separate binary predictor vari-
ables were used for maternal and paternal diabetes.
Kaplan- Meier survival analyses with log- rank tests were 
used for categorical analyses, comparing the presence or 
absence of family history of diabetes or abnormal birth 
weight.
For the analysis of abnormal birth weight as a risk factor 
and for interactions of birth weight and family history, 
Cox proportional hazards regression was employed. Age 
at clozapine initiation, length of clozapine treatment, 
and gender were used as predictors. Given the known 
U- shaped relationship between birth weight, we included 
birth weight as a quadratic variable. The exponentiated 
model coefficient (eB) is presented as HR and its 95% 
CI. Birth weight and its quadratic value were used in 100 
g units.
Descriptive statistics and subgroup differences were 
examined using χ2 tests, t tests, and analysis of variance 
as appropriate. All analyses were conducted using IBM 
SPSS V.25.0 for Mac, with the significance level set at 
alpha=0.05.
ResulTs
The final sample included 190 clozapine- treated patients 
with schizophrenia. Of these, data on family history of 
T2DM were available for 183, birthweight data for 112 
and data on both variables for 109. The characteristics of 
the sample are summarized in table 1.
To test for potential biases, we compared those without 
birthweight data (n=78) with those with abnormal birth 
weight (n=75) and normal birth weight (n=37) and 
found no differences in terms of age at the time of the 
study (p=0.108), age at clozapine initiation (p=0.051), 
length of clozapine treatment (p=0.34), family history 
of diabetes (p=0.68) or gender (p=0.76). Details of these 
comparisons can be found in the online supplementary 
material.
Prevalence of glucose dysregulation in direct group 
comparisons
The prevalence of any glucose dysregulation in the entire 
sample (n=183) was 24.7% (16.8% for T2DM). The preva-
lence increased with the duration of clozapine treatment, 
from 5% in those with less than 5 years on clozapine, to 
31% after 10–20 years and 28% after more than 20 years 
(F1,187=5.097, df=2, p=0.007; linear- term F1,2=7.240, df=1, 
p=0.008).
In the group with family history data (n=183), the prev-
alence of glucose dysregulation was numerically greater 
in those with family history of diabetes compared with 
those without (28.3% vs 16.1%), but this difference was 
not statistically significant (χ2=3.315; df=1; p=0.057).
The prevalence of glucose dysregulation varied across 
the birthweight categories, as shown in figure 1A. Of 
the 112 individuals, 37 were in the high- risk birthweight 
categories: <2501 g (n=10), 2501–3000 g (n=19), and 
>4500 g (n=8). The prevalence of glucose dysregulation 
was 45.5% in this high- risk subgroup, compared with an 
overall prevalence of 27.8% in the other three non- high- 
risk categories, but this difference did not reach statis-
tical significance (χ2=3.262; df=1; p=0.058).
Role of parental diabetes, controlled by confounders
In the Kaplan- Meier survival analysis (n=183) accounting 
for length of treatment with clozapine, a greater inci-
dence of glucose dysregulation was seen among those 
with a parental history of diabetes (Mantel- Cox log- rank 
χ2=4.331; p=0.037; figure 2).
The Cox regression analysis (n=183) showed that 
parental diabetes (HR=2.145; CI 1.116 to 4.121; p=0.022) 
and age at clozapine initiation (HR=1.05; CI 1.015 
to 1.087; p=0.005) were significant predictors, while 
gender was not (HR=0.658; CI 0.328 to 1.319; p=0.238). 
When we examined the role of paternal and maternal 
diabetes separately, only paternal diabetes (HR=2.751; CI 
1.246 to 6.071; p=0.012) and age of clozapine initiation 
(HR=1.048; CI 1.013 to 1.085; p=0.007) were significant 
predictors, and not maternal diabetes (HR=1.358; CI 
0.571 to 3.229; p=0.489) or gender (HR=0.629; CI 0.313 
to 1.266; p=0.194).
Role of birth weight, controlled by confounders
Using the Kaplan- Meier survival analysis (n=112), a 
greater incidence of glucose dysregulation was seen in 
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Figure 1 Effect of birth weight on glucose dysregulation onset in clozapine- treated patients. (A) Percentage of any 
glucose dysregulation by birthweight category in the 112 clozapine- treated cases. (B) Kaplan- Meier survival plot for glucose 
dysregulation onset using 112 cases, of which 37 had abnormal birth weight (in red; 15 events, 22 censored) and 75 had 
normal birth weight (in blue; 18 events, 57 censored).
the high- risk birthweight group (Mantel- Cox log- rank 
χ2=4.565; p=0.033; figure 1B).
For the Cox proportional hazards regression survival 
analysis (n=112), the quadratic element of birth weight 
was used to account for the U- shaped risk. Birth weight2 
(HR=0.999; CI 0.998 to 1.000; p=0.026) and age of 
clozapine initiation (HR=1.092; CI 1.045 to 1.142; 
p<0.001) were significant predictors, while gender was 
not (HR=1.167; CI 0.507 to 2.686; p=0.716).
exploring the independence of birth weight and family history 
and alternative models
A Cox proportional hazards regression survival model 
(n=109) showed that age at clozapine initiation 
(HR=1.098; CI 1.051 to 1.149; p<0.001), parental history 
of diabetes (HR=2.299; CI 1.002 to 5.272; p=0.049) and 
birth weight2 (HR=0.999; CI 0.998 to 1.000; p=0.013) 
were all significant, while gender was not (HR=0.517; CI 
0.545 to 3.346; p=0.517).
Birth weight did not differ between individuals with 
and without a family history of diabetes (mean 3478 g, 
SD 829.1 vs mean 3429 g, SD 704 respectively; t=−0.288; 
df=107; p=0.77). Birth weight, or its quadratic value 
(birth weight2), did not correlate with age at clozapine 
initiation (n=112; r=0.073, p=0.44 and r=0.097, p=0.31, 
respectively).
To examine if these predictors interacted in deter-
mining the risk of glucose dysregulation, we created the 
following interaction terms: (1) parental diabetes:birth 
weight2; (2) parental diabetes:age of clozapine initiation, 
and (3) birth weight2:age of clozapine initiation. We ran 
separate models including each of the interaction terms 
and compared them with the basic model above. None 
of these models provided better model fits than the basic 
model (omnibus tests of model coefficients: p=0.908, 
p=0.548 and p=0.728, respectively), that is, no interaction 
was found between variables.
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Figure 3 Role of abnormal birth weight and/or family history of diabetes in glucose dysregulation onset using Kaplan- Meier 
survival plot of 112 cases, of which 58 had no risk factors (in blue; 10 events, 48 censored), 47 had one risk factor (in red; 19 
events, 28 censored) and 7 had both risk factors (in green; four events, 3 censored).
Figure 2 Kaplan- Meier survival plot of glucose dysregulation onset, using 183 cases, of which 148 had no family history of 
diabetes (in blue; 33 events, 115 censored) and 35 had family history of diabetes (in red; 13 events, 22 censored).
effect of extreme birth weight and family history on diabetes 
onset
In the sample, 58 subjects (51.8%) had none of these two 
risk factors, 47 (42%) had one and 7 (6.3%) had both risk 
factors. Glucose dysregulation was seen in 17.2% of those 
without risk factors, compared with 40.4% of those with 
one risk factor and 57.1% of those with two risk factors 
(χ2=9.467, p=0.009; linear- by- linear association=9.301, 
p=0.002). Using the Kaplan- Meier survival analysis, a 
greater and earlier incidence of glucose dysregulation 
was seen among those with two risk factors compared with 
one risk factor or none (Mantel- Cox log- rank χ2=14.118; 
p=0.001; figure 3).
Finally, we explored a clinical question of the risk of 
developing diabetes in patients with zero, one, or two 
risk factors depending on age at clozapine initiation (see 
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Table 2 Risk of developing diabetes by number of risk 
factors and age at clozapine initiation (less than 25 years 
old, between 25 and 35, and above 35 years old)
All ages 
(%)
<25 
(%)
25–35 
(%)
>35 
(%)
No risk factors (n) 20 12 27 18
Family history of diabetes 
(n)
40 23 33 75
Extreme birth weight (n) 56 30 43 90
Family history and 
abnormal birth weight (n)
80 50 100 100
Data only include cases with more than 10 years of clozapine 
treatment.
table 2). For this analysis, we limited the data to those who 
had been on clozapine for at least 10 years, to exclude 
individuals who might have not yet developed diabetes 
during the relatively short follow- up in this sample.
dIsCussIOn
In this study, we found that both abnormal birth weight 
and parental history of diabetes were associated with 
diabetes onset in clozapine- treated patients with schizo-
phrenia. Both were independent risk factors, which did 
not interact but had an additive effect. Among those 
patients treated with clozapine for a decade, up to 80% of 
cases with both factors and half of those with one factor 
developed glucose dysregulation. The results cannot be 
attributed to differences in length of clozapine treat-
ment, gender, or age of clozapine initiation, as these 
factors were controlled using the Cox regression survival 
analysis. Considering that 48% of all cases had at least 
one risk factor and 6% had both risk factors, and should 
our results be replicated, there might be a substantial 
proportion of patients for whom strategies to reduce the 
risk of developing diabetes could be implemented.
Our sample is comparable with other studies in schizo-
phrenia, in terms of its male predominance (~80%), with 
the prevalence of diabetes (16.8%) and glucose dysreg-
ulation (24.7%) being twice that in the general popula-
tion.9 The prevalence found is in line with other studies 
in clozapine- treated patients.23 We excluded individuals 
with a prior diagnosis of diabetes and those for whom the 
date of diagnosis was not available; including the latter 
would have raised the prevalence to 21%. Our sample 
included individuals who had a very long exposure to 
clozapine (37% had been on clozapine for over 20 years; 
table 1). We combined longitudinal assessment in the 
clinic with patients’ primary care records to increase 
the completeness and reliability of the information and 
reduce the false negative rate.
The results replicate and extend others’ work. Family 
history of diabetes is a risk factor for diabetes onset in the 
general population26 and in people with schizophrenia.7 14 
A recent meta- analysis has calculated the risk to be four-
fold in those with a family history of diabetes, similar to 
what is found in the general population.27 Interestingly, 
we found that paternal diabetes conferred a greater risk 
for developing glucose dysregulation. This is in line with 
findings in first- episode psychosis by our group in Spain14 
and in schizophrenia conducted in the USA7 and the 
Netherlands,28 which suggest a specific role of paternal 
diabetes in this patient group that has not been described 
in the general population.29 One potential explanation 
would be that fathers tend to be older than mothers, and 
therefore more likely to have developed diabetes, but 
in our sample the paternal and maternal age differed 
by just 3 years, which makes this explanation unlikely. 
The consistency of the finding regarding gender- specific 
family risk along different studies and phases of illness 
deserves further study. We also replicated the linear asso-
ciation of length of antipsychotic treatment and age at 
diabetes onset found in schizophrenia.23
A more novel part of our study is the role of abnormal 
birth weight. Compared with previous studies20 that have 
examined the impact of low birth weight exclusively, we 
considered the impact of both extremes of birth weight 
and we also used birth weight as a continuous variable. 
Recent meta- analytic evidence15 using more than four 
million general population cases shows that both low 
(<3000 g) and very high (>4500 g) birth weight increase 
the risk of diabetes onset. Our results mimic the same 
U- shaped curve (figure 1A), with increased risk for 
extremely low, low, and extremely high birth weights. 
While there are no previous studies on the effect of birth 
weight on diabetes onset in people with schizophrenia, 
the results align with previous work on birthweight modu-
lation of weight gain in schizophrenia,20 30 a metabolic 
complication commonly associated with diabetes. Impor-
tantly, the present study adds clinical significance, as here 
we used well- established markers of glucose dysregula-
tion (diabetes or pre- diabetic state).
The excess of diabetes seen in patients with schizo-
phrenia predates the antipsychotic era,31 although 
the prevalence has increased since the use of second- 
generation antipsychotics.5 Glucose intolerance has also 
been described in drug- naïve first- episode psychosis,32 33 
suggesting that some patients might have an innate predis-
position, although there are no studies associating these 
earlier abnormalities with the development of overt 
clinical conditions such as diabetes. Epidemiological 
evidence from the famine studies in the Netherlands 
and China has linked diabetes and schizophrenia onset 
with low birth weight,34 35 reflecting a common develop-
mental origin and risk factor. We think that our study 
adds evidence to this hypothesis.
The mechanism by which extreme birth weight 
increases the risk of diabetes onset is still unclear,16 
and our work here was not aimed to address this. The 
leading hypothesis in metabolic science, first developed 
by Hales and Barker,17 posits that in- utero adversity leads 
to epigenetic changes that allow the fetus to cope with 
a predicted adverse environment by prioritizing energy 
storage. In a postnatal environment with abundance of 
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resources, these adaptations are disadvantageous and 
lead to metabolic complications. Schizophrenia is, at 
least in part, a neurodevelopmental condition36 which 
might predispose to metabolic complications,37 and this 
predisposition is perhaps unmasked by the effects of anti-
psychotic medication in increasing appetite,5 changes in 
diet19 and decrease in resting metabolic rate.38 Nonethe-
less, it might also be interesting to see whether or not 
the risk factors found here could be replicated in other 
neurodevelopmental conditions with increased risk of 
developing metabolic complications, such as attention- 
deficit/hyperactivity disorder,39 or in individuals with 
schizophrenia taking other antipsychotic medication.
Most importantly, our results provide support for the 
use of these simple clinical variables to identify cases 
that will benefit from early preventive metabolic inter-
ventions. In this sense, the additive effect of risk factors 
might have some implications. Having abnormal birth 
weight and a positive family history (seen in 6% of cases) 
was almost certainly associated with glucose dysregulation 
(table 2). A practical consequence would be considering 
whether hypoglycemic pharmacological treatment in 
this group is advisable. Indeed, there is a case for adding 
metformin to the treatment of people on clozapine, both 
to help reduce weight gain40 and because of the high risk 
of developing diabetes,41 after or in conjunction with 
behavioral changes. Considering that trials for behavioral 
changes fail to show long- term efficacy,42 a pragmatic 
approach would be to suggest adding metformin to all 
high- risk cases (ie, those with abnormal birth weight and 
family history). For cases with one risk factor, lowering 
the threshold of metformin initiation to those with pre- 
diabetes might also be advisable. Nevertheless, further 
studies to replicate our findings should be conducted 
before making firm recommendations.
Our work has some strengths but also limitations. We 
used survival analysis, controlling for key factors such as 
length of clozapine treatment or age at the time of first 
clozapine prescription, and we included subjects with 
very long exposure to clozapine. However, the study used 
birth weight and family history information collected from 
patients and relatives, which might lack accuracy. We put 
in place conditions for the validity of the information and 
we and others have used a similar approach before,20 but 
studies using recorded rather than recalled data might 
be needed. The group with birthweight data had exactly 
the same amount of time on clozapine as those without 
birthweight data (~16 years on average), although they 
had started 3 years younger. We also defined glucose 
dysregulation (which included glucose intolerance) as 
the main outcome, rather than a more selective outcome 
of T2DM. This was in part driven by the clinical relevance 
of both conditions, given the likely progression from 
glucose intolerance to diabetes,24 and the sample size of 
our study. Studies using larger data sets will be needed 
to replicate our results in those with T2DM only. Sample 
size in general was limited, with just 112 cases in which 
birth weight was available, and thus large samples should 
be used to replicate our findings. Prospective studies and 
different statistical methods could also be designed to 
explore causality rather than the association as we found 
here. Nevertheless, we would like to highlight that schizo-
phrenia is relatively uncommon compared with T2DM 
(0.7% vs 15% of the general population) and no more 
than 15% of patients with schizophrenia are treated with 
clozapine, which inevitably makes studies of clozapine- 
treated patients smaller compared with studies of T2DM 
in the general population. We did not include informa-
tion regarding BMI, as data on BMI at baseline or at the 
time of diabetes diagnosis were not available, or the rate 
of BMI increase. However, BMI only marginally increases 
the risk of diabetes in clozapine patients,4 and more 
importantly we have previously described how BMI is 
modulated by birth weight in clozapine- treated patients20 
and in first- episode psychosis. Therefore, the common 
risk factor (abnormal birth weight) would impact both 
BMI and glucose dysregulation. Finally, we did not address 
the issue of psychiatric comedication in this group, which 
might have had an impact on the development of glucose 
dysregulation. The sample size and complex medication 
regimens during the long follow- up (40% more than 
20 years) made this infeasible in our study and perhaps 
could be addressed with larger samples.
In summary, we conclude that abnormal birth weight 
and family history of diabetes are independent risk factors 
for glucose dysregulation onset in clozapine- treated 
patients. Should these results be replicated, it might help 
clinicians to identify high- risk subjects easily and imple-
ment preventive interventions, including the use of phar-
macological agents along with changes in lifestyle.
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